Overview

The purpose of this study is to develop and test a new communication training intervention called Hematolo-GIST to help oncologists communicate with patients about their lymphoma diagnosis and advance care planning.

Eligibility

Inclusion Criteria:

Hematologists

• Currently a hemotologic oncologist providing care to patients with DLBCL

Patients

• Per medical record, is being treated by a hematologic oncologist participating in this study
• Per medical record, has a diagnosis of DLBCL-transformed follicular lymphoma (TFL) and primary mediastinal B-cell lymphoma (PMBCL) which are histologically similar and clinically treated as large-cell lymphoma
• Per medical record, receipt of ≥ 4 cycles of first-line therapy or 2 cycles of later-line therapy as best response to chemotherapy or relapse ≤ 12 months after autologous stem cell transplant (ACST)
• Per medical record, received an anti-CD20 monoclonal antibody or an anthracycline as one of their qualifying regiments
• Self-identify as Black and/or White
• Per medical record, 18 years of age or older
• Per self-report, fluent in English** ** Language verification: Prior to enrollment, patients will be asked the following two questions by a Clinical Research Coordinator (CRC) to verify English fluency necessary for participation in the study:
  1. How well do you speak English? (must respond "very well" or "well" when given the choices of Very well, Well, Not well, Not at all, Don't know, or Refused)
  2. What is your preferred language for healthcare? (must respond English)

Exclusion Criteria:

Hematologists

• Per self-report, planning to leave the cancer center in the next 12 months

Patients

• Moderately or severely cognitively impaired as demonstrated by Short Portable Mental Status Questionnaire score > 4
• Per research staff judgment and/or self-report, too ill or weak to complete study procedures
• Per medical record or self-report, receiving hospice care at the time of enrollment